S

Sanofi

Global pharma company; vaccines and R&D

Key Account Manager - Multiple Myeloma, Central Ontario

Full-TimeDeadline 10/23/26
No salary listed
Senior
Bachelor's
Toronto, ON, Canada
RemoteTravel is approximately 60% of the time, including national and occasional international travel.
Sales & Account ManagementAccount Management

About the job

Requirements
  • A Bachelor's degree in Science, Business, or a related field is required.
  • At least 5 years of specialty pharmaceutical sales experience is required.
  • A demonstrated track record of high performance in complex, specialist-driven markets is required.
  • A deep understanding of Hematology and Oncology, including treatment landscapes, patient journeys, and market access, is required.
  • Experience working with institutional accounts, reimbursement processes, and formulary approvals is required.
  • Strong business acumen and the ability to interpret market data and translate insights into action are required.
  • Proven excellence in consultative, value-based selling and account strategy execution is required.
  • The ability to influence without authority and lead through collaboration across cross-functional teams is required.
  • Strong communication skills and the ability to translate complex clinical information into meaningful conversations with senior clinical stakeholders are required.
  • Curiosity and learning agility, with the ability to develop fluency in disease state, clinical data, and product complexity, are required.
  • Exceptional planning, prioritization, and territory management skills are required.
  • The ability to work independently in a field-based environment with a high degree of ownership is required.
  • Proficiency with customer relationship management systems and digital engagement tools is required.
  • The candidate must be willing and able to travel approximately 60% of the time, including national and occasional international travel.
  • The candidate must be flexible to work evenings and weekends as required by business needs.
  • The candidate must be eligible for a company vehicle under the Sanofi Fleet Program, complete required safety training, and maintain an acceptable driving record.
Responsibilities
  • Meet or exceed sales and performance objectives while managing territory resources responsibly.
  • Develop, execute, and continuously refine a data-driven territory business plan incorporating market dynamics, customer insights, and brand strategy.
  • Identify risks and opportunities in a timely way and adjust the approach to protect and grow business results.
  • Analyze market trends, customer needs, and competitive insights to inform strategy and identify new growth opportunities.
  • Build and maintain value-based partnerships with Hematologic Oncologists, nurses, pharmacists, and key allied health professionals.
  • Serve as the primary commercial contact for Sanofi within accounts and coordinate cross-functional support from Marketing, Medical, Patient Support, and other internal partners.
  • Understand account decision-making structures and adapt the engagement approach accordingly.
  • Support institutions and key accounts by guiding formulary and budget approval processes.
  • Conduct high-quality scientific exchange aligned with the Product Monograph and Sanofi's ethical and compliance standards.
  • Articulate the clinical and patient value of Sanofi therapies within evolving Multiple Myeloma treatment paradigms.
  • Educate and train healthcare teams on the clinical benefits, administration, and real-world use of Sanofi therapies.
  • Facilitate peer-to-peer learning between community-based and academic oncologists to optimize Multiple Myeloma treatment pathways.
  • Build local advocacy through consistent, credible relationships with key stakeholders.
  • Support regional and national educational programs, learning initiatives, and congresses.
  • Maintain a current and accurate territory and account database to inform national planning and execution.
  • Use omnichannel and digital tools to enhance customer engagement and drive impactful conversations.
  • Execute all activities in alignment with Sanofi's regulatory, legal, and compliance standards.
  • Maintain timely and accurate customer relationship management documentation, call reporting, expense management, and other administrative requirements.
  • Complete all mandatory training and steward company assets.
  • Participate in national and regional meetings, conferences, and training programs.
Desired Qualifications
  • Specialty pharmaceutical sales experience in Oncology or Hematology is strongly preferred.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...